HK1181673A1 - Long-term storage of non-glycosylated recombinant human g-csf g-csf - Google Patents

Long-term storage of non-glycosylated recombinant human g-csf g-csf

Info

Publication number
HK1181673A1
HK1181673A1 HK13109084.3A HK13109084A HK1181673A1 HK 1181673 A1 HK1181673 A1 HK 1181673A1 HK 13109084 A HK13109084 A HK 13109084A HK 1181673 A1 HK1181673 A1 HK 1181673A1
Authority
HK
Hong Kong
Prior art keywords
csf
long
recombinant human
term storage
glycosylated recombinant
Prior art date
Application number
HK13109084.3A
Other languages
English (en)
Chinese (zh)
Inventor
Klaus Graumann
Helmut Lerch
Thomas Lauber
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of HK1181673A1 publication Critical patent/HK1181673A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK13109084.3A 2010-06-22 2013-08-05 Long-term storage of non-glycosylated recombinant human g-csf g-csf HK1181673A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10166915A EP2399572A1 (fr) 2010-06-22 2010-06-22 Stockage à long terme de G-CSF humain recombinant non glycosylé
US36056210P 2010-07-01 2010-07-01
PCT/EP2011/060454 WO2011161165A1 (fr) 2010-06-22 2011-06-22 Stockage de longue durée de g-csf humain recombiné non glycosylé

Publications (1)

Publication Number Publication Date
HK1181673A1 true HK1181673A1 (en) 2013-11-15

Family

ID=43414064

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13109084.3A HK1181673A1 (en) 2010-06-22 2013-08-05 Long-term storage of non-glycosylated recombinant human g-csf g-csf

Country Status (12)

Country Link
US (3) US8449873B2 (fr)
EP (2) EP2399572A1 (fr)
JP (1) JP5837924B2 (fr)
CN (1) CN102946863B (fr)
AU (1) AU2011268944B2 (fr)
CA (1) CA2802932C (fr)
ES (1) ES2534334T3 (fr)
HK (1) HK1181673A1 (fr)
HR (1) HRP20150372T1 (fr)
RS (1) RS53884B1 (fr)
SI (1) SI2585044T1 (fr)
WO (1) WO2011161165A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104906053B (zh) * 2015-06-12 2018-01-16 北京四环生物制药有限公司 注射用重组人粒细胞刺激因子冻干粉针剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR871067B (en) 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6956023B1 (en) * 2001-04-19 2005-10-18 University Of Florida Materials and methods for providing nutrition to neonates
GB0323968D0 (en) 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
DE10348550A1 (de) 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
WO2005042024A1 (fr) 2003-11-04 2005-05-12 Lek Pharmaceuticals D.D. Composition pharmaceutique stable comportant le facteur stimulant les colonies de granulocytes
WO2007034509A2 (fr) 2005-09-19 2007-03-29 Zenotech Laboratories Limited Formulation d'un facteur de stimulation de colonies de granulocytes de recombinaison et procede de preparation correspondant
DE102006009437A1 (de) * 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
EP2124889A2 (fr) * 2007-02-16 2009-12-02 Wyeth a Corporation of the State of Delaware Formulations de protéine contenant du sorbitol
JP5349452B2 (ja) 2007-04-05 2013-11-20 サンド アクチエンゲゼルシャフト 安定な水性ｇ‐ｃｓｆ製剤
JP2010536906A (ja) * 2007-08-27 2010-12-02 バイオジェネリクス アーゲー Ｇ−ｃｓｆの液体製剤
TW201138831A (en) * 2009-09-30 2011-11-16 Prolong Pharmaceuticals Inc Modified granulocyte colony stimulating factor (G-CSF)

Also Published As

Publication number Publication date
US8784794B2 (en) 2014-07-22
CA2802932A1 (fr) 2011-12-29
CN102946863A (zh) 2013-02-27
HRP20150372T1 (hr) 2015-05-08
AU2011268944A1 (en) 2013-01-17
US9387233B2 (en) 2016-07-12
AU2011268944B2 (en) 2014-05-01
EP2585044A1 (fr) 2013-05-01
US20140294756A1 (en) 2014-10-02
US20130164253A1 (en) 2013-06-27
EP2399572A1 (fr) 2011-12-28
EP2585044B1 (fr) 2015-01-07
ES2534334T3 (es) 2015-04-21
SI2585044T1 (sl) 2015-04-30
CN102946863B (zh) 2015-06-10
WO2011161165A1 (fr) 2011-12-29
CA2802932C (fr) 2018-03-06
JP5837924B2 (ja) 2015-12-24
JP2013529618A (ja) 2013-07-22
US20120042613A1 (en) 2012-02-23
US8449873B2 (en) 2013-05-28
RS53884B1 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
IL230120B (en) Preparations containing recombinant iduronate-2-sulfatase and their uses
EP2509568A4 (fr) Compositions de soins de la peau
HK1183802A1 (en) Therapeutic oral composition
EP2646468A4 (fr) Compositions anti-ngf et leur utilisation
ZA201209436B (en) Improved recombinant human follicle-stimulating hormone
IL221808B (en) Method for obtaining biologically active recombinant human g-csf
ZA201208413B (en) Skin treatment composition
EP2612676A4 (fr) Utilisation d'un dimère de g-csf dans le traitement de la neutropénie
EP2627391A4 (fr) Cathéter hydrophobe et composition associée
IL223292A0 (en) Stabilized human immunoglobulin composition
ZA201302952B (en) Fungicidal compositions and methods of use
EP2708230A4 (fr) Composition pour utilisation externe sur la peau pour des maladies inflammatoires
EP2773417A4 (fr) Dérivation médicale implantable
HK1184779A1 (en) Novel compound and medical use thereof
ZA201208568B (en) Skin treatment composition
EP2563804A4 (fr) Préparation de polypeptides et de leurs sels
HK1181673A1 (en) Long-term storage of non-glycosylated recombinant human g-csf g-csf
PT2555790T (pt) USO TERAPÊUTICO DA PROTEÍNA DE ß MICROGLOBULINA
HUE051050T2 (hu) Ráksejtek ellen hatásos rekombináns emberi IgM ellenanyag
EP2637501A4 (fr) Compositions fongicides et procédés d'utilisation
EP2773418A4 (fr) Dérivation médicale active implantable
ZA201102156B (en) Improved processing of recombinant human g-csf
HU1000599D0 (en) Skin care composition
TWM385287U (en) Tilting-angle-adjusting structure of chair
TWM385982U (en) Improved structure of combination chair

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210621